CVE-2020-14525Philips Clinical Collaboration Platform Improper Neutralization of Script in Attributes in a Web Page
Updated under an hour ago ()
Does this affect you?
It affects Philips Clinical Collaboration Platform. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.47%, higher than 39% of scored CVEs.
Do this next
Free account, 1 product
Philips Clinical Collaboration Platform, Versions 12.2.1 and prior, does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output used as a webpage that is served to other users.
- CVSS
- 3.5 LOW (v3.1, CNA)CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
- Weakness (CWE)
- CWE-83
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.47% (percentile 39)
- Assigned by
- icscert
- NVD analysis
- Modified
- Record last updated
- Jun 4, 2025
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
Philips Clinical Collaboration Platform philips:clinical_collaboration_platform (from the name) | before 12.2.1 | CNA record |
philips clinical_collaboration_platform philips:clinical_collaboration_platform | through 12.2.1 | NVD |
References
- https://us-cert.cisa.gov/ics/advisories/icsma-20-261-01x-refsource-misc, third-party-advisory, us-government-resource
- https://www.philips.com/a-w/security/security-advisories/product-security-2020.html#2020_archive
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.